Deltex Medical Regulatory News (DEMG)

31 May 2017

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

Deltex granted patent for its innovative Combined Blood Flow and Blood Pressure Monitor

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that it has been granted a new patent.

Deltex Medical has been granted patent coverage for its innovative Combined Blood Flow and Blood Pressure Monitor. The granted coverage is for UK, Germany, France, Spain and Sweden. Coverage in the USA has been 'allowed' at this stage and the Company expects the US patent to be formally granted in the second half of the year.

The device filing covers use of Doppler measurements of central blood flow, measured with either oesophageal or suprasternal ultrasound probes, in conjunction with blood pressure signals whether measured in arteries, veins or by way of non invasive pressure cuffs placed on the arm or fingers. The coverage also includes the combination of a venous oxygen saturation sensor with the flow and pressure measurements.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"This patent is very important. It underpins and protects our combination of Doppler ultrasound flow signals with blood pressure inputs on a single monitoring platform including the current CardioQ-ODM+ platform.

"Doing this offers us unique possibilities to advance haemodynamic monitoring. We recently received a €50,000 EU grant to support the clinical development of innovative new 'TruVue' graphical user intrerfaces which are driven by combining flow and pressure signals."

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.